Long Ideas - Acquiring non-dilutive capital is always encouraging for a development-stage biotech company, and investors should take note when a company improves its balance sheet without hurting … Continue Reading
Read NowLong Ideas - Cadence (CADX) was a compelling buy last year as the sales ramp for its IV acetaminophen formulation began to improve. A position since Mr. King … Continue Reading
Read NowMost Popular - Shares of Cadence Pharmaceuticals (CADX) have run too high too fast, and although fundamentals have improved significantly in the last year, we believe the stock … Continue Reading
Read NowLong Ideas - Chatter on the specialty pharma front is that Endo Health’s (ENDP) newly hired CEO will be shaking hands with shareholders in a multi-city road show … Continue Reading
Read NowMost Popular - On the American equity exchanges, trading halts occur primarily for two reasons: news dissemination and extreme volatility. Halting an equity for a pending regulatory decision is often … Continue Reading
Read NowLong Ideas - The EMA’s advisory body took investors by surprise on Friday and announced that they would be recommending Halozyme (HALO) and Baxter’s (BAX) HyQvia for approval … Continue Reading
Read NowLong Ideas - Friday morning, Halozyme Therapeutics (HALO) and one of its commercial partners, Baxter International (BAX), announced that the European Union’s Committee for Medicinal Products for Human Use (CHMP) … Continue Reading
Read Now